Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics

The BenchMark ULTRA PLUS system will be available to European Union countries in July 2022 and to the United States and in the Asia-Pacific market in September 2022, followed by a worldwide roll out in 2023

Roche has announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick test results so clinicians can make timely decisions regarding a patient’s care journey.

Thomas Schinecker, CEO of Roche Diagnostics said, “With the BenchMark ULTRA PLUS, we are pleased to offer an advanced tissue staining platform, co-developed with lab professionals. Waiting for a diagnosis is often one of the most stressful times for patients. This system enables pathologists to provide quick and accurate results that help inform patient treatment options.”

Cancer and other abnormal cells can be characterised by biochemical markers from within the cells. By applying chemical solutions to tissue on glass slides with the BenchMark ULTRA PLUS, a healthcare professional can identify these markers to determine the presence or absence of key drivers that feed the unhealthy cells and, in many cases, the type of therapy that could be used to combat them.

The new system has several innovations such as new intuitive software, remote monitoring features, an integrated touchscreen, and a more environmentally sustainable waste system and product packaging.

The BenchMark ULTRA PLUS system will be available to European Union countries in July 2022 and to the United States and in the Asia-Pacific market in September 2022, followed by a worldwide roll out in 2023.